O Shaughnessy Asset Management LLC Buys Shares of 31,375 Masimo Co. (NASDAQ:MASI)

O Shaughnessy Asset Management LLC purchased a new stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 31,375 shares of the medical equipment provider's stock, valued at approximately $5,186,000. O Shaughnessy Asset Management LLC owned 0.06% of Masimo as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Orion Portfolio Solutions LLC increased its stake in shares of Masimo by 2.1% in the 4th quarter. Orion Portfolio Solutions LLC now owns 4,778 shares of the medical equipment provider's stock valued at $790,000 after purchasing an additional 97 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in Masimo by 10.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 6,392 shares of the medical equipment provider's stock valued at $1,057,000 after purchasing an additional 608 shares during the period. New Age Alpha Advisors LLC purchased a new stake in shares of Masimo in the fourth quarter valued at approximately $656,000. Norges Bank acquired a new position in shares of Masimo during the 4th quarter worth approximately $5,520,000. Finally, Vanguard Group Inc. lifted its position in shares of Masimo by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock valued at $758,182,000 after buying an additional 66,215 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

Remove Ads

Insider Activity

In other news, Director Craig B. Reynolds sold 2,053 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares in the company, valued at $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.70% of the company's stock.

Masimo Price Performance

MASI stock traded up $5.96 during mid-day trading on Monday, reaching $150.36. The company's stock had a trading volume of 1,133,100 shares, compared to its average volume of 645,075. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company's 50 day moving average is $173.23 and its two-hundred day moving average is $163.63. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The stock has a market cap of $8.12 billion, a PE ratio of 103.70 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. The firm had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Equities research analysts expect that Masimo Co. will post 4.1 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research report on Wednesday, February 26th. Raymond James upped their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research report on Friday, December 27th. Wells Fargo & Company lifted their price objective on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, Piper Sandler boosted their price objective on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.